1. Impact of Hodgkin or non-Hodgkin lymphoma and their treatments on sperm aneuploidy: a prospective study by the French CECOS network 
Guillaume Martinez, Ph.D., Marie Walschaerts, Ph.D., Marine Le Mitouard, B.Sc., Remi Borye, M.Sc., Claire Thomas, M.D., Jacques Auger, M.D., Ph.D., Isabelle Berthaut, Ph.D., Florence Brugnon, M.D., Ph.D., Myriam Daudin, M.D., Nathalie Moinard, D.Pharm., Célia Ravel, M.D., Ph.D., Jacqueline Saias, M.D., Ethel Szerman, Ph.D., Nathalie Rives, M.D., Ph.D., Sylviane Hennebicq, M.D., Ph.D., Louis Bujan, M.D., Ph.D. 
Fertility and Sterility 
Volume 107, Issue 2, Pages e5 (February 2017)
DOI: /j.fertnstert
Copyright © 2016 American Society for Reproductive Medicine Terms and Conditions

2. Figure 1
Mean percentages of chromosomal abnormalities and SEMs before and during posttreatment follow-up: total chromosomal abnormalities, disomy, 24X/Y,+18, and diploidy. *P<.05, pre- and posttreatment difference. #P<.05, difference between controls and lymphoma patients. Means and SDs are given at each time point.
Fertility and Sterility  , e5DOI: ( /j.fertnstert )
Copyright © 2016 American Society for Reproductive Medicine Terms and Conditions

3. Supplemental Figure 1 Design of the prospective study.
Fertility and Sterility  , e5DOI: ( /j.fertnstert )
Copyright © 2016 American Society for Reproductive Medicine Terms and Conditions

4. Supplemental Figure 2
Mean percentages of total chromosomal abnormalities and SEMs before and during posttreatment follow-up according to type of treatment (ABVD ± radiotherapy, or CHOP/MOPP-ABV) and in the control group. *P<.05, pre- and posttreatment difference. #P<.05, difference between controls and lymphoma patients.
Fertility and Sterility  , e5DOI: ( /j.fertnstert )
Copyright © 2016 American Society for Reproductive Medicine Terms and Conditions